Dynavax Technologies Corporation Share Price Nasdaq
Equities
US2681581029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 285M 22.42B | Sales 2025 * | 350M 27.56B | Capitalization | 1.49B 117B |
---|---|---|---|---|---|
Net income 2024 * | 18M 1.42B | Net income 2025 * | 48M 3.78B | EV / Sales 2024 * | 3.28 x |
Net cash position 2024 * | 556M 43.76B | Net cash position 2025 * | 683M 53.73B | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
71.2
x | P/E ratio 2025 * |
31.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Latest transcript on Dynavax Technologies Corporation
Managers | Title | Age | Since |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 31/12/04 |
David Novack
PSD | President | 62 | 24/03/13 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 02/11/09 |
Peggy Phillips
BRD | Director/Board Member | 70 | 31/07/06 |
Dan Kisner
BRD | Director/Board Member | 77 | 21/07/10 |
1st Jan change | Capi. | |
---|---|---|
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |